Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 33,900 shares, a growth of 226.0% from the September 30th total of 10,400 shares. Based on an average daily volume of 33,400 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.2% of the company’s shares are sold short.

Theratechnologies Stock Down 0.8 %

NASDAQ:THTX traded down $0.01 on Friday, hitting $1.24. The stock had a trading volume of 8,896 shares, compared to its average volume of 45,138. The stock has a market cap of $57.02 million, a price-to-earnings ratio of -6.53 and a beta of 1.41. The company has a fifty day moving average price of $1.27 and a two-hundred day moving average price of $1.32. Theratechnologies has a 1-year low of $0.88 and a 1-year high of $2.58.

Theratechnologies (NASDAQ:THTX) last posted its quarterly earnings data on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $22.60 million for the quarter. During the same period in the prior year, the firm earned ($0.03) earnings per share. As a group, analysts anticipate that Theratechnologies will post 0.03 earnings per share for the current year.

Institutional Investors Weigh In On Theratechnologies

A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC raised its position in Theratechnologies Inc. (NASDAQ:THTX) by 26.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,311 shares of the company’s stock after acquiring an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned approximately 0.29% of Theratechnologies worth $163,000 as of its most recent SEC filing.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.